Showing results (601-610 of 735) with videos related to
Sort By:
Pageof 74
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 TrialPaolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.European Journal of Cancer (Oxford, England : 1990)|December 24, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring systemJames Larkin, Michael P Brown, Ana M Arance, et al.Nature Methods|April 11, 2025
Error-corrected flow-based sequencing at whole-genome scale and its application to circulating cell-free DNA profilingAlexandre Pellan Cheng, Adam J Widman, Anushri Arora, et al.European Journal of Cancer (Oxford, England : 1990)|March 22, 2015
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaDirk Schadendorf, Mayur M Amonkar, Daniil Stroyakovskiy, et al.Nature Cancer|June 26, 2023
Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancerLuigi Perelli, Federica Carbone, Li Zhang, et al.European Journal of Cancer (Oxford, England : 1990)|January 24, 2018
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective studySara Valpione, Matteo S Carlino, Johanna Mangana, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401Reinhard Dummer, Pippa Corrie, Ralf Gutzmer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup TrialTim Eisen, Eleni Frangou, Bhavna Oza, et al.Journal for Immunotherapy of Cancer|September 29, 2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, et al.Annals of the Rheumatic Diseases|April 25, 2020
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitorsMarie Kostine, Axel Finckh, Clifton O Bingham, et al.Pageof 74